Yi Li, Ph.D.

Vice president of medical and clinical operations

Dr. Li has 15  years of experience in global translational research, clinical development, and medical affairs. She was the Medical Director and National Medical Head of Mix-Products at Jiangsu Hengrui Pharmaceutical, where she developed clinical development plan and medical strategies for over 100 clinical studies in therapeutic areas such as Oncology, Surgery, ICU, Rheumatology & Immunology, Hematology, Pediatrics, Nephrology, etc. From 2014 to 2018, Dr. Li was the Sr. Medical Manager and TA head in multi therapeutic areas at Abbott China, where she oversaw medical and business assessment for 50+ potential license-in products. Prior to Abbott China, Dr. Li was a Medical Advisor for Novartis in the Infectious Disease Franchise and Brand Physician in AstraZeneca where she addressed high impact IPS to support brand growth and managed a dozen of clinical trials. In parallel she joined Shanghai Jiao-Tong University Renji Hospital as a Resident Doctor and Ph.D. supervisor responsible for the grants of “National Natural Science Foundation”. From 2007 to 2011, Dr. Li worked as a Ph.D. fellow at Erasmus Medical Center in the Netherlands, discovered the role of IL-6/IL-17 signaling and JAK/STAT/SOCS pathway in autoimmune disease and GI oncology. She is an Advisor Board member of China Medical Affairs Committee and the Chairman of Advisory Board in Real World Data and Evidence. Dr. Li received her Ph.D. of Medicine from Erasmus University in the Netherlands, M.D. from Wuhan University Zhongnan Hospital, and her EMBA from Shanghai Jiao-Tong University. Dr. Li has 9 book publications, 20+ manuscript publications, and 10+ Chinese guidelines contribution in GI Oncology, Respiratory Disease, Analgesia, Surgery.